氯米帕明和米氮平治疗抑郁症的疗效比较  

Efficacy of chlorimipramine and mirtazapine in depression

作　　者：何柱国[1] 许国富 孙祺章[1] 梁景省[1] 邓德清[1] 廖秀霞[1] 

机构地区：[1]广州市精神病医院,510370 [2]广东省阳春市民福精神病医院

出　　处：《上海精神医学》2006年第5期279-280,293,共3页Shanghai Archives of Psychiatry

摘　　要：目的比较氯米帕明和米氮平治疗抑郁症的疗效。方法80例门诊抑郁症患者随机分为氯米帕明和米氮平治疗组,疗程8周,用汉密尔顿抑郁量表(HAMD),临床疗效总评量表(CGI)和副反应症状量表(TESS)在治疗前及治疗后第2、4、8周末行评定。结果治疗8周后氯米帕明组和米氮平组HAMD减分率分别为71．89%和71．74%,两组治疗前、后比较差异均有显著性(P＜0．01),但两组间比较差异无显著性(P＞0．05)。氯米帕明副反应发生率33．25%,米氮平22．21%两组间比较差异有显著性(P＜0．05)。结论米氮平治疗抑郁症疗效与氯米帕明相当,副反应轻。Objective： To compare the efficacy and safety of chlorimipramine and mirtazapine in the treatment of depression. Methods： 80 outpatients with a diagnosis of depression were randomly assigned to ehlorimipramine or mirtazapine groups for 8 weeks treatment. Efficacy and safety were assessed by HAMD （Hamilton Rating Scale for depression） , CGI（ Clinical Global Impression rating scale） and TESS. Assessments were performed at weeks 0,2,4 and 8. Results ：The responses by wk 8 （ decrease in HAMD scores for 71.89% and 71. 74% from baseline respectively） were observed in patients treated with chlorimipramine and the Mirtazapine. Both medication groups showed a significant improvement over the 8 weeks of treatment （P 〈 0. 05 ）. There was no statistically significant difference between the mean ＋/-SEM HAMD scores of two groups （P〉0.05）. The rates of side effects on chlorimipramine and mirtazapine were greatly different （P 〈 0 05）. Conclusion：Mirtazapine is as effective as chlorimioramine in the treatment of depression with less side effects.

关 键 词：氯米帕明 米氮平 抑郁症 疗效 

分 类 号：R749.4[医药卫生—神经病学与精神病学]